ASH 2021 | NK cells in hematological malignancies
Krish Patel
• 13 Dec 2021
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, describes the advantages of natural killer (NK) cell therapy in treating lymphomas and leukemias. NK cells innately target tumors and therefore have a different safety profile compared to chimeric antigen receptor (CAR) T-cell therapy, where NK cell therapy is less likely to result in immune effector cell-associated neurotoxicity syndrome (ICANS) or cytokine release syndrome (CRS). NK cells additionally can contain a CAR, as in the case of FT596, and due to their off-the-shelf nature, can be administered in a short space of time. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
